How to individualize arterial hypertension treatment in type 2 diabetes mellitus?

Authors

  • Solange Houssay José María Ramos Mejía Hospital, Autonomous City of Buenos Aires, Argentina
  • Silvana Alejandra Milrad Manuel Rocca Rehabilitation Hospital, Autonomous City of Buenos Aires, Argentina
  • Ángela Luongo Pueyrredón Medical Center, Banfield, Province of Buenos Aires, Argentina
  • Carolina Gómez Martín Comprehensive Center of Endocrinology and Diabetes (CENDIA), Concordia, Entre Ríos, Argentina
  • Diego Wappner INFANT Foundation, Autonomous City of Buenos Aires, Argentina
  • Guillermo Dieuzeide University of Buenos Aires, Autonomous City of Buenos Aires, Argentina

DOI:

https://doi.org/10.47196/diab.v56i2Sup.538

Keywords:

diabetes, arterial hypertension

Abstract

In patients with diabetes mellitus (DM) and hypertension (HP), blood pressure (BP) goals should be individualized considering cardiovascular risk, potential adverse effects of antihypertensive medications, cost, and patient preferences.
In people with DM and high cardiovascular risk, a BP target <130/80 mmHg would be appropriate if it can be achieved safely. If cardiovascular risk is low, treat hypertension with a target <140/90 mmHg. In pregnant women with gestational diabetes mellitus (GDM) and preexisting hypertension, a BP target of 110-135/85 mmHg is suggested to reduce the risk of eclampsia and minimize intrauterine growth restriction.

Author Biographies

Solange Houssay, José María Ramos Mejía Hospital, Autonomous City of Buenos Aires, Argentina

University Specialist in Nutrition and Medical Clinic; Staff Physician, Nutrition and Diabetes Unit, Department of Medicine, José María Ramos Mejía Hospital; Associate professor of the Nutrition Chair, University of Buenos Aires (UBA); Coordinator of the Committee on Arterial Hypertension and cardiovascular risk factors, Argentine Diabetes Society (SAD)

Silvana Alejandra Milrad, Manuel Rocca Rehabilitation Hospital, Autonomous City of Buenos Aires, Argentina

Specialist in Medical Clinic and Nutrition; Head of Emergency Services of the Manuel Rocca Rehabilitation Hospital, Government of the Autonomous City of Buenos Aires; Secretary of the Arterial Hypertension and Cardiovascular Risk Factors Committee, Argentine Diabetes Society (SAD)

Ángela Luongo, Pueyrredón Medical Center, Banfield, Province of Buenos Aires, Argentina

Nutrition Specialist

Carolina Gómez Martín, Comprehensive Center of Endocrinology and Diabetes (CENDIA), Concordia, Entre Ríos, Argentina

Specialist in Internal Medicine, University of Buenos Aires (UBA), specialized in Diabetes, Argentine Diabetes Society (SAD); Co-director of the Comprehensive Center for Endocrinology and Diabetes (CENDIA)

Diego Wappner, INFANT Foundation, Autonomous City of Buenos Aires, Argentina

Specialist in Internal Medicine and Medical Clinic, Master in Diabetes, Master in Cardiovascular Disease; Responsible for the area of ??Chronic Non-Communicable Diseases (NCCD) Fundación INFANT

Guillermo Dieuzeide, University of Buenos Aires, Autonomous City of Buenos Aires, Argentina

Doctor of Medicine, University of Buenos Aires (UBA), specialist in Endocrinology, Council for Certification and Recertification of Medical Specialties/Argentine Society of Endocrinology and Metabolism/Medical Council of the Province of Buenos Aires (CREM/SAEM/CMPBA); Favaloro University Professor, Head of the Endocrinology and Diabetes Service, Hospital Nuestra. Mrs. del Carmen

References

I. Kannel WB, Wilson PW, Zhang TJ. The epidemiology of impaired glucose tolerance and hypertension. Am Heart J 1991 Apr;121(4 Pt 2):1268-73.

II. Tarnow L, Rossing P, Gall MA, Nielsen FS, Parving HH. Prevalence of arterial hypertension in diabetic patients before and after the JNC-V. Diabetes Care 1994 Nov;17 Suppl 11:1247-51.

III. Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000 Aug 12;321(Suppl) 7258:412-9.

IV. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993 Feb;16 Suppl 2:434-44.

V. Do DV, Wang X, Vedula SS, Marrone M, Sleilati G, Hawkins BS, et al. Blood pressure control for diabetic retinopathy. Cochrane Database Syst Rev 2015 Jan 31;1:CD006127.

VI. Emdin CA, Rahimi K, Neal B, Callender T, Perkovic V, Patel A. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA 2015 Feb 10;313 Suppl 6:603-15.

VII. Brunström M, Carlberg B. Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses. BMJ 2016 Feb 24;352:i717-227.

VIII. Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment on outcome incidence in hypertension. Should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analysis of randomized trials. J Hypertens 2017 May;35 Suppl 5:922-44.

IX. Brazy PC, Stead WW, Fitzwilliam JF. Progression of renal insufficiency: role of blood pressure. Kidney International 1989;35:670-4. doi.org/10.1038/ki.1989.37 231. Acceso: mayo 2022.

X. Hannedouche T, Albouze G, Chauveau P, Lacour B, Jungers P. Effects of blood pressure and antihypertensive treatment on progression of advanced chronic renal failure. American Journal of Kidney Diseases 1993;21:131-7. doi: 10.1016/0272-6386(93)70104-7 232. Acceso: mayo 2022.

XI. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. NEJM 1994;330:877-84. doi: 10.1056/nejm199403313301301. Acceso: mayo 2022.

XII. Fang M, Wang D, Coresh J, Selvin E. Trends in diabetes treatment and control in U.S. adults, 1999-2018. NEJM 2021;384 (23):2219-28.

XIII. Williams B, Mancia G, Spiering W, Agabiti-Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018 Sep 1;39Suppl 33:3021-104.

XIV. Mc Murray John JV, Packer M, Akshay S Desai, et al. Angiotensin-neprilisin inhibition versus enalapril in heart failure. NEJM 2014;371:993-1004.

XV. Seferovic JP, et al. Effect of sacubitril-valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post hoc analysis from de PARADIGM HF trial. Lancet Diabetes & Endocrinology 2017;Suppl 5:333-40.

XVI. Jordan J, Stinkens R, Jax T, S Engeli et al. Improved insulin sensitivity with angiotensin receptor neprilysin inhibition in individuals with obesity and hypertension. Clinical Pharmacology & Therapeutics 2017;101 (Issue 2):254-263.

XVII. Nerenberg KA, Zarnke KB, Leung AA, Dasgupta K, Butalia S, McBrien K, et al. Hypertension Canada’s 2018 Guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children. Can J Cardiol 2018 May;34 Suppl 5:506-25.

XVIII. National Clinical Guideline Centre (UK). Hypertension. 2011 Aug (Citado: 13/02/18) Disponible en: www.ncbi.nlm.nih.gov/books/NBK83274/. Acceso: mayo 2022.

XIX. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb. ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASG/ASPC/NMA/PCNA. Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2018 Oct 23;138 Suppl 17: e484–594.

XX. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes 2021. Diabetes Care 2021;44 Suppl. 1: S125–S150. doi: 10.2337/dc21.S010. Acceso: mayo 2022.

XXI. Guía de Práctica Clínica Nacional sobre Prevención, Diagnóstico y Tratamiento de la Hipertensión Arterial (HTA), 2019. Buenos Aires, Argentina. Dirección Nacional de Promoción de la Salud y Control de Enfermedades Crónicas No Transmisibles. Ministerio de Salud y Desarrollo Social de la Nación. Disponible en: http://www.msal.gob.ar/ent/index.php/informacion-equipos-de-salud/guias-de-practica-clinica, consultado mayo 2022.

Downloads

Published

2022-08-01

How to Cite

Houssay, S., Milrad, S. A., Luongo, Ángela, Gómez Martín, C., Wappner, D., & Dieuzeide, G. (2022). How to individualize arterial hypertension treatment in type 2 diabetes mellitus?. Journal of the Argentine Society of Diabetes, 56(2Sup), 48–52. https://doi.org/10.47196/diab.v56i2Sup.538

Issue

Vol. 56 No. 2Sup (2022): May/Agost 2022

Section

Recommendations

License

Copyright (c) 2022 on behalf of the authors. Reproduction rights: Argentine Diabetes Society

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Dirección Nacional de Derecho de Autor, Exp. N° 5.333.129. Instituto Nacional de la Propiedad Industrial, Marca «Revista de la Sociedad Argentina de Diabetes - Asociación Civil» N° de concesión 2.605.405 y N° de disposición 1.404/13.

La Revista de la SAD está licenciada bajo Licencia Creative Commons Atribución – No Comercial – Sin Obra Derivada 4.0 Internacional.

Por otra parte, la Revista SAD permite que los autores mantengan los derechos de autor sin restricciones.

 

Similar Articles

1 2 3 4 5 6 > >> 

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)

<< < 1 2 3 4 5 6 > >>